RxDoctor Payments Data

Samuel Nussbaumer, MD

Interventional Cardiology · Bedford, TXNPI 1073515508

Payments from drug & device makers

$16,377in general payments, 2019–2025

Across 298 payments — averaging $54.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ultragenyx Pharmaceutical Inc.$9K
  • Boston Scientific$1K
  • Abbott$803
  • Abiomed$503
  • E.r. Squibb & Sons, L.L.C.$431
  • Novartis$405
  • plus $4K from 30 others

What the payments were for

  • Consulting fees$7,15044%
  • Travel & lodging$2,78017%
  • Food & beverage$6,25038%
  • Education$1971%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,377 in reported general payments places this provider in the 60th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$162,190
Medicare patients
1,206
Services billed
2,559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban271$298,970
XareltoRivaroxaban184$195,761
EntrestoSacubitril/Valsartan96$108,668
JardianceEmpagliflozin96$97,542
Repatha SureclickEvolocumab34$33,788
VascepaIcosapent Ethyl12$8,252
Nebivolol Hcl101$6,247
Metoprolol Succinate351$4,251
Bisoprolol Fumarate141$3,764
Ranolazine ErRanolazine39$3,601
Telmisartan87$3,303
Amiodarone Hcl88$3,286
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid31$2,219
ClopidogrelClopidogrel Bisulfate215$2,096
Rosuvastatin Calcium164$2,087

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$248$298,970271 claims
Johnson & JohnsonXarelto$315$195,761184 claims
NovartisEntresto$405$108,66896 claims
Boehringer IngelheimJardiance$204$97,54296 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Bedford

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →